Asymmetry Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-20,571
| Closed | -$1.47M | – | 32 |
|
|
2018
Q4 | $1.47M | Sell |
20,571
-2,562
| -11% | -$183K | 4.06% | 9 |
|
|
2018
Q3 | $2.84M | Sell |
23,133
-3,777
| -14% | -$464K | 2.63% | 16 |
|
|
2018
Q2 | $2.64M | Sell |
26,910
-2,915
| -10% | -$286K | 2.6% | 15 |
|
|
2018
Q1 | $2.47M | Buy |
29,825
+5,030
| +20% | +$417K | 3.09% | 11 |
|
|
2017
Q4 | $1.92M | Sell |
24,795
-26,702
| -52% | -$2.07M | 2.61% | 13 |
|
|
2017
Q3 | $3.16M | Buy |
51,497
+17,467
| +51% | +$1.07M | 3.66% | 11 |
|
|
2017
Q2 | $1.57M | Buy |
+34,030
| New | +$1.57M | 1.86% | 21 |
|
|
2016
Q4 | – | Sell |
-37,644
| Closed | -$1.91M | – | 23 |
|
|
2016
Q3 | $1.91M | Buy |
37,644
+6,973
| +23% | +$353K | 3.31% | 12 |
|
|
2016
Q2 | $1.39M | Sell |
30,671
-32,517
| -51% | -$1.48M | 2.55% | 17 |
|
|
2016
Q1 | $2.5M | Buy |
63,188
+22,300
| +55% | +$882K | 6.51% | 6 |
|
|
2015
Q4 | $2.31M | Sell |
40,888
-8,612
| -17% | -$487K | 3.5% | 11 |
|
|
2015
Q3 | $1.97M | Buy |
+49,500
| New | +$1.97M | 4.39% | 10 |
|